Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

Otsuka Pharmaceutical and Ionis Pharmaceuticals said their experimental therapy met the primary endpoint in a late-stage trial for a rare inherited form of ALS. The positive pivotal-study result could support regulatory filings and improve the commercial outlook for both companies' rare-disease pipelines.